Use of clinically available PPAR agonists for heart failure; do the risks outweigh the potential benefits?

scientific article published on June 2012

Use of clinically available PPAR agonists for heart failure; do the risks outweigh the potential benefits? is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.2174/1874467211205020255
P8608Fatcat IDrelease_gsrmuyg2cfd7zhyybfgfcgv4s4
P698PubMed publication ID22122455

P2093author name stringSatyam Sarma
P433issue2
P921main subjectheart failureQ181754
P304page(s)255-263
P577publication date2012-06-01
P1433published inCurrent molecular pharmacologyQ26842459
P1476titleUse of clinically available PPAR agonists for heart failure; do the risks outweigh the potential benefits?
P478volume5

Reverse relations

cites work (P2860)
Q37739117A Clinical Perspective of Anti-Fibrotic Therapies for Cardiovascular Disease.
Q49908591Interrelationship between diabetes mellitus and heart failure: the role of peroxisome proliferator-activated receptors in left ventricle performance.
Q26746998Peroxisome Proliferator-Activated Receptor-γ Is Critical to Cardiac Fibrosis
Q36219006Rational screening of peroxisome proliferator-activated receptor-γ agonists from natural products: potential therapeutics for heart failure.

Search more.